keyword
MENU ▼
Read by QxMD icon Read
search

Anil K Sood

keyword
https://www.readbyqxmd.com/read/29669287/zranb1-is-an-ezh2-deubiquitinase-and-a-potential-therapeutic-target-in-breast-cancer
#1
Peijing Zhang, Zhenna Xiao, Shouyu Wang, Mutian Zhang, Yongkun Wei, Qinglei Hang, Jongchan Kim, Fan Yao, Cristian Rodriguez-Aguayo, Baochau N Ton, Minjung Lee, Yumeng Wang, Zhicheng Zhou, Liyong Zeng, Xiaoyu Hu, Sarah E Lawhon, Ashley N Siverly, Xiaohua Su, Jia Li, Xiaoping Xie, Xuhong Cheng, Liang-Chiu Liu, Hui-Wen Chang, Shu-Fen Chiang, Gabriel Lopez-Berestein, Anil K Sood, Junjie Chen, M James You, Shao-Cong Sun, Han Liang, Yun Huang, Xianbin Yang, Deqiang Sun, Yutong Sun, Mien-Chie Hung, Li Ma
Although EZH2 enzymatic inhibitors have shown antitumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here we identify ZRANB1 as the EZH2 deubiquitinase. ZRANB1 binds, deubiquitinates, and stabilizes EZH2. Depletion of ZRANB1 in breast cancer cells results in EZH2 destabilization and growth inhibition. Systemic delivery of ZRANB1 small interfering RNA (siRNA) leads to marked antitumor and antimetastatic effects in preclinical models of triple-negative breast cancer (TNBC)...
April 17, 2018: Cell Reports
https://www.readbyqxmd.com/read/29661830/sustained-adrenergic-signaling-promotes-intratumoral-innervation-through-bdnf-induction
#2
Julie K Allen, Guillermo N Armaiz-Pena, Archana S Nagaraja, Nouara C Sadaoui, Tatiana Ortiz, Robert Dood, Merve Ozcan, Danielle M Herder, Monika Haemerrle, Kshipra M Gharpure, Rajesha Rupaimoole, Rebecca Previs, Sherry Y Wu, Sunila Pradeep, Xiaoyun Xu, Hee Dong Han, Behrouz Zand, Heather J Dalton, Morgan Taylor, Wei Hu, Justin Bottsford-Miller, Myrthala Moreno-Smith, Yu Kang, Lingegowda S Mangala, Cristian Rodriguez-Aguayo, Vasudha Sehgal, Erika L Spaeth, Prahlad T Ram, Stephen Tc Wong, Frank C Marini, Gabriel Lopez-Berestein, Steve W Cole, Susan K Lutgendorf, Mariella diBiasi, Anil K Sood
Mounting clinical and preclinical evidence supports a key role for sustained adrenergic signaling in the tumor microenvironment as a driver of tumor growth and progression. However, the mechanisms by which adrenergic neurotransmitters are delivered to the tumor microenvironment are not well understood. Here we present evidence for a feedforward loop whereby adrenergic signaling leads to increased tumoral innervation. In response to catecholamines, tumor cells produced brain-derived neurotrophic factor (BDNF) in an ADRB3/cAMP/Epac/JNK-dependent manner...
April 16, 2018: Cancer Research
https://www.readbyqxmd.com/read/29657130/the-platelet-lifeline-to-cancer-challenges-and-opportunities
#3
REVIEW
Monika Haemmerle, Rebecca L Stone, David G Menter, Vahid Afshar-Kharghan, Anil K Sood
Besides their function in limiting blood loss and promoting wound healing, experimental evidence has highlighted platelets as active players in all steps of tumorigenesis including tumor growth, tumor cell extravasation, and metastasis. Additionally, thrombocytosis in cancer patients is associated with adverse patient survival. Due to the secretion of large amounts of microparticles and exosomes, platelets are well positioned to coordinate both local and distant tumor-host crosstalk. Here, we present a review of recent discoveries in the field of platelet biology and the role of platelets in cancer progression as well as challenges in targeting platelets for cancer treatment...
March 19, 2018: Cancer Cell
https://www.readbyqxmd.com/read/29622464/a-comprehensive-pan-cancer-molecular-study-of-gynecologic-and-breast-cancers
#4
Ashton C Berger, Anil Korkut, Rupa S Kanchi, Apurva M Hegde, Walter Lenoir, Wenbin Liu, Yuexin Liu, Huihui Fan, Hui Shen, Visweswaran Ravikumar, Arvind Rao, Andre Schultz, Xubin Li, Pavel Sumazin, Cecilia Williams, Pieter Mestdagh, Preethi H Gunaratne, Christina Yau, Reanne Bowlby, A Gordon Robertson, Daniel G Tiezzi, Chen Wang, Andrew D Cherniack, Andrew K Godwin, Nicole M Kuderer, Janet S Rader, Rosemary E Zuna, Anil K Sood, Alexander J Lazar, Akinyemi I Ojesina, Clement Adebamowo, Sally N Adebamowo, Keith A Baggerly, Ting-Wen Chen, Hua-Sheng Chiu, Steve Lefever, Liang Liu, Karen MacKenzie, Sandra Orsulic, Jason Roszik, Carl Simon Shelley, Qianqian Song, Christopher P Vellano, Nicolas Wentzensen, John N Weinstein, Gordon B Mills, Douglas A Levine, Rehan Akbani
We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of four gynecological types plus breast. Our aims were to identify shared and unique molecular features, clinically significant subtypes, and potential therapeutic targets. We found 61 somatic copy-number alterations (SCNAs) and 46 significantly mutated genes (SMGs). Eleven SCNAs and 11 SMGs had not been identified in previous TCGA studies of the individual tumor types. We found functionally significant estrogen receptor-regulated long non-coding RNAs (lncRNAs) and gene/lncRNA interaction networks...
April 1, 2018: Cancer Cell
https://www.readbyqxmd.com/read/29617668/pan-cancer-analysis-of-lncrna-regulation-supports-their-targeting-of-cancer-genes-in-each-tumor-context
#5
Hua-Sheng Chiu, Sonal Somvanshi, Ektaben Patel, Ting-Wen Chen, Vivek P Singh, Barry Zorman, Sagar L Patil, Yinghong Pan, Sujash S Chatterjee, Anil K Sood, Preethi H Gunaratne, Pavel Sumazin
Long noncoding RNAs (lncRNAs) are commonly dysregulated in tumors, but only a handful are known to play pathophysiological roles in cancer. We inferred lncRNAs that dysregulate cancer pathways, oncogenes, and tumor suppressors (cancer genes) by modeling their effects on the activity of transcription factors, RNA-binding proteins, and microRNAs in 5,185 TCGA tumors and 1,019 ENCODE assays. Our predictions included hundreds of candidate onco- and tumor-suppressor lncRNAs (cancer lncRNAs) whose somatic alterations account for the dysregulation of dozens of cancer genes and pathways in each of 14 tumor contexts...
April 3, 2018: Cell Reports
https://www.readbyqxmd.com/read/29594152/ionizing-radiation-induces-endothelial-inflammation-and-apoptosis-via-p90rsk-mediated-erk5-s496-phosphorylation
#6
Hang Thi Vu, Sivareddy Kotla, Kyung Ae Ko, Yuka Fujii, Yunting Tao, Jan Medina, Tamlyn Thomas, Megumi Hada, Anil K Sood, Pankaj Kumar Singh, Sarah A Milgrom, Sunil Krishnan, Keigi Fujiwara, Nhat-Tu Le, Jun-Ichi Abe
Adverse cardiovascular events are a leading nonmalignant cause of morbidity and mortality among cancer survivors who have been exposed to ionizing radiation (IR), but the exact mechanism of the cardiovascular complications induced by IR remains unclear. In this study we investigated the potential role of the p90RSK-ERK5 module in regulating IR-induced endothelial cell inflammation and apoptosis. Whole body radiation of mice with 2 Gy γ-ray significantly increased endothelial VCAM-1 expression; especially in the disturbed flow area in vivo ...
2018: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29553098/association-of-biobehavioral-factors-with-non-coding-rnas-in-cervical-cancer
#7
Qiyu Liu, Chong Lu, Wanjun Dai, Ke Li, Jing Xu, Yunke Huang, Guiling Li, Yu Kang, Anil K Sood, Congjian Xu
In order to elucidate the mechanisms underlying the biobehavioral factors responsible for cervical cancer from the perspective of lncRNAs. Tumor samples were obtained from patients with stage Ib-IIb squamous cervical cancer, which were divided into high- and low-risk groups according to biobehavioral risk factors. A lncRNA + mRNA microarray was performed, and the results were validated using qRT-PCR. Gene ontology (GO), pathway, and lncRNA-mRNA co-expression analysis were performed to predict the potential functions of the differentially expressed transcripts...
2018: Bioscience Trends
https://www.readbyqxmd.com/read/29456965/corrigendum-enhanced-cytotoxic-effects-of-combined-valproic-acid-and-the-aurora-kinase-inhibitor-ve465-on-gynecologic-cancer-cells
#8
Yanfang Li, Tao Liu, Cristina Ivan, Jie Huang, De-Yu Shen, John J Kavanagh, Robert C Bast, Siqing Fu, Wei Hu, Anil K Sood
[This corrects the article on p. 58 in vol. 3, PMID: 23519775.].
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29396402/tuning-microtubule-dynamics-to-enhance-cancer-therapy-by-modulating-fer-mediated-crmp2-phosphorylation
#9
Yiyan Zheng, Ritika Sethi, Lingegowda S Mangala, Charlotte Taylor, Juliet Goldsmith, Ming Wang, Kenta Masuda, Mohammad Karaminejadranjbar, David Mannion, Fabrizio Miranda, Sandra Herrero-Gonzalez, Karin Hellner, Fiona Chen, Abdulkhaliq Alsaadi, Ashwag Albukhari, Donatien Chedom Fotso, Christopher Yau, Dahai Jiang, Sunila Pradeep, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Stefan Knapp, Nathanael S Gray, Leticia Campo, Kevin A Myers, Sunanda Dhar, David Ferguson, Robert C Bast, Anil K Sood, Frank von Delft, Ahmed Ashour Ahmed
Though used widely in cancer therapy, paclitaxel only elicits a response in a fraction of patients. A strong determinant of paclitaxel tumor response is the state of microtubule dynamic instability. However, whether the manipulation of this physiological process can be controlled to enhance paclitaxel response has not been tested. Here, we show a previously unrecognized role of the microtubule-associated protein CRMP2 in inducing microtubule bundling through its carboxy terminus. This activity is significantly decreased when the FER tyrosine kinase phosphorylates CRMP2 at Y479 and Y499...
February 2, 2018: Nature Communications
https://www.readbyqxmd.com/read/29388135/isolation-of-extracellular-rna-from-serum-plasma
#10
Justyna Filant, Parham Nejad, Anu Paul, Bridget Simonson, Srimeenakshi Srinivasan, Xuan Zhang, Leonora Balaj, Saumya Das, Roopali Gandhi, Louise C Laurent, Anil K Sood
Extracellular RNAs are initiating increased interest due to their potentials in serving as novel biomarkers, mediators of intercellular communication, and therapeutic applications. As a newly emerging field, one of the main obstacles is the lack of standardized protocols for RNA isolations. Here we describe protocols for commercially available kits that have been modified to yield consistent results for isolation of extracellular RNA from both whole serum/plasma and extracellular vesicle-enriched serum/plasma samples...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29386184/lpa-induces-metabolic-reprogramming-in-ovarian-cancer-via-a-pseudohypoxic-response
#11
Ji Hee Ha, Rangasudhagar Radhakrishnan, Muralidharan Jayaraman, Mingda Yan, Jeremy D Ward, Kar-Ming Fung, Katherine Moxley, Anil K Sood, Ciro Isidoro, Priyabrata Mukherjee, Yong Sang Song, Danny N Dhanasekaran
Although hypoxia has been shown to reprogram cancer cells toward glycolytic shift, the identity of extrinsic stimuli that induce metabolic reprogramming independent of hypoxia, especially in ovarian cancer, is largely unknown. In this study, we use patient-derived ovarian cancer cells and high-grade serous ovarian cancer cell lines to demonstrate that lysophosphatidic acid (LPA), a lipid growth factor and GPCR ligand whose levels are substantially increased in ovarian cancer patients, triggers glycolytic shift in ovarian cancer cells...
April 15, 2018: Cancer Research
https://www.readbyqxmd.com/read/29251630/cancer-associated-fibroblasts-regulate-endothelial-adhesion-protein-lpp-to-promote-ovarian-cancer-chemoresistance
#12
Cecilia S Leung, Tsz-Lun Yeung, Kay-Pong Yip, Kwong-Kwok Wong, Samuel Y Ho, Lingegowda S Mangala, Anil K Sood, Gabriel Lopez-Berestein, Jianting Sheng, Stephen Tc Wong, Michael J Birrer, Samuel C Mok
The molecular mechanism by which cancer-associated fibroblasts (CAFs) confer chemoresistance in ovarian cancer is poorly understood. The purpose of the present study was to evaluate the roles of CAFs in modulating tumor vasculature, chemoresistance, and disease progression. Here, we found that CAFs upregulated the lipoma-preferred partner (LPP) gene in microvascular endothelial cells (MECs) and that LPP expression levels in intratumoral MECs correlated with survival and chemoresistance in patients with ovarian cancer...
February 1, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29249663/hn1l-promotes-triple-negative-breast-cancer-stem-cells-through-lepr-stat3-pathway
#13
Yi Liu, Dong Soon Choi, Jianting Sheng, Joe E Ensor, Diana Hwang Liang, Cristian Rodriguez-Aguayo, Amanda Polley, Steve Benz, Olivier Elemento, Akanksha Verma, Yang Cong, Helen Wong, Wei Qian, Zheng Li, Sergio Granados-Principal, Gabriel Lopez-Berestein, Melissa D Landis, Roberto R Rosato, Bhuvanesh Dave, Stephen Wong, Dario Marchetti, Anil K Sood, Jenny C Chang
Here, we show that HEMATOLOGICAL AND NEUROLOGICAL EXPRESSED 1-LIKE (HN1L) is a targetable breast cancer stem cell (BCSC) gene that is altered in 25% of whole breast cancer and significantly correlated with shorter overall or relapse-free survival in triple-negative breast cancer (TNBC) patients. HN1L silencing reduced the population of BCSCs, inhibited tumor initiation, resensitized chemoresistant tumors to docetaxel, and hindered cancer progression in multiple TNBC cell line-derived xenografts. Additionally, gene signatures associated with HN1L correlated with shorter disease-free survival of TNBC patients...
January 9, 2018: Stem Cell Reports
https://www.readbyqxmd.com/read/29246304/therapeutic-targeting-of-axl-receptor-tyrosine-kinase-inhibits-tumor-growth-and-intraperitoneal-metastasis-in-ovarian-cancer-models
#14
Pinar Kanlikilicer, Bulent Ozpolat, Burcu Aslan, Recep Bayraktar, Nilgun Gurbuz, Cristian Rodriguez-Aguayo, Emine Bayraktar, Merve Denizli, Vianey Gonzalez-Villasana, Cristina Ivan, Ganesh L R Lokesh, Paola Amero, Silvia Catuogno, Monika Haemmerle, Sherry Yen-Yao Wu, Rahul Mitra, David G Gorenstein, David E Volk, Vittorio de Franciscis, Anil K Sood, Gabriel Lopez-Berestein
Despite substantial improvements in the treatment strategies, ovarian cancer is still the most lethal gynecological malignancy. Identification of drug treatable therapeutic targets and their safe and effective targeting is critical to improve patient survival in ovarian cancer. AXL receptor tyrosine kinase (RTK) has been proposed to be an important therapeutic target for metastatic and advanced-stage human ovarian cancer. We found that AXL-RTK expression is associated with significantly shorter patient survival based on the The Cancer Genome Atlas patient database...
December 15, 2017: Molecular Therapy. Nucleic Acids
https://www.readbyqxmd.com/read/29243000/rna-interference-based-therapy-and-its-delivery-systems
#15
Xiuhui Chen, Lingegowda S Mangala, Cristian Rodriguez-Aguayo, Xianchao Kong, Gabriel Lopez-Berestein, Anil K Sood
RNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful systemic delivery. Effective delivery systems are essential to enable the full therapeutic potential of RNAi...
March 2018: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/29242937/paclitaxel-with-and-without-pazopanib-for-persistent-or-recurrent-ovarian-cancer-a-randomized-clinical-trial
#16
Debra L Richardson, Michael W Sill, Robert L Coleman, Anil K Sood, Michael L Pearl, Siobhan M Kehoe, Michael E Carney, Parviz Hanjani, Linda Van Le, Xun C Zhou, Angeles Alvarez Secord, Heidi J Gray, Lisa M Landrum, Heather A Lankes, Wei Hu, Carol Aghajanian
Importance: Ovarian cancer is the leading cause of gynecologic cancer deaths in the United States. Pazopanib is an oral, multitarget kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptors α and β; and proto-oncogene receptor tyrosine kinase (c-KIT). Objective: To estimate the progression-free survival (PFS) hazard ratio (HR) of weekly paclitaxel and pazopanib compared with weekly paclitaxel and placebo in women with recurrent ovarian cancer...
February 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29237804/inhibiting-nuclear-phospho-progesterone-receptor-enhances-antitumor-activity-of-onapristone-in-uterine-cancer
#17
Yan Huang, Wei Hu, Jie Huang, Fangrong Shen, Yunjie Sun, Cristina Ivan, Sunila Pradeep, Robert Dood, Monika Haemmerle, Dahai Jiang, Lingegowda S Mangala, Kyunghee Noh, Jean M Hansen, Heather J Dalton, Rebecca A Previs, Archana S Nagaraja, Michael McGuire, Nicholas B Jennings, Russell Broaddus, Robert L Coleman, Anil K Sood
Although progesterone receptor (PR)-targeted therapies are modestly active in patients with uterine cancer, their underlying molecular mechanisms are not well understood. The clinical use of such therapies is limited because of the lack of biomarkers that predict response to PR agonists (progestins) or PR antagonists (onapristone). Thus, understanding the underlying molecular mechanisms of action will provide an advance in developing novel combination therapies for cancer patients. Nuclear translocation of PR has been reported to be ligand-dependent or -independent...
February 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29228548/macrophage-depletion-through-colony-stimulating-factor-1-receptor-pathway-blockade-overcomes-adaptive-resistance-to-anti-vegf-therapy
#18
Yasmin A Lyons, Sunila Pradeep, Sherry Y Wu, Monika Haemmerle, Jean M Hansen, Michael J Wagner, Alejandro Villar-Prados, Archana S Nagaraja, Robert L Dood, Rebecca A Previs, Wei Hu, Yang Zhao, Duncan H Mak, Zhilan Xiao, Brenda D Melendez, Gregory A Lizee, Imelda Mercado-Uribe, Keith A Baggerly, Patrick Hwu, Jinsong Liu, Willem W Overwijk, Robert L Coleman, Anil K Sood
Anti-angiogenesis therapy has shown clinical benefit in patients with high-grade serous ovarian cancer (HGSC), but adaptive resistance rapidly emerges. Thus, approaches to overcome such resistance are needed. We developed the setting of adaptive resistance to anti-VEGF therapy, and performed a series of in vivo experiments in both immune competent and nude mouse models. Given the pro-angiogenic properties of tumor-associated macrophages (TAMs) and the dominant role of CSF1R in macrophage function, we added CSF1R inhibitors following emergence of adaptive resistance to anti-VEGF antibody...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29212026/differential-effects-of-egfl6-on-tumor-versus-wound-angiogenesis
#19
Kyunghee Noh, Lingegowda S Mangala, Hee-Dong Han, Ningyan Zhang, Sunila Pradeep, Sherry Y Wu, Shaolin Ma, Edna Mora, Rajesha Rupaimoole, Dahai Jiang, Yunfei Wen, Mian M K Shahzad, Yasmin Lyons, MinSoon Cho, Wei Hu, Archana S Nagaraja, Monika Haemmerle, Celia S L Mak, Xiuhui Chen, Kshipra M Gharpure, Hui Deng, Wei Xiong, Charles V Kingsley, Jinsong Liu, Nicholas Jennings, Michael J Birrer, Richard R Bouchard, Gabriel Lopez-Berestein, Robert L Coleman, Zhiqiang An, Anil K Sood
Angiogenesis inhibitors are important for cancer therapy, but clinically approved anti-angiogenic agents have shown only modest efficacy and can compromise wound healing. This necessitates the development of novel anti-angiogenesis therapies. Here, we show significantly increased EGFL6 expression in tumor versus wound or normal endothelial cells. Using a series of in vitro and in vivo studies with orthotopic and genetically engineered mouse models, we demonstrate the mechanisms by which EGFL6 stimulates tumor angiogenesis...
December 5, 2017: Cell Reports
https://www.readbyqxmd.com/read/29185273/trends-of-low-grade-serous-ovarian-carcinoma-in-the-united-states
#20
Koji Matsuo, Hiroko Machida, Brendan H Grubbs, Anil K Sood, David M Gershenson
No abstract text is available yet for this article.
January 2018: Journal of Gynecologic Oncology
keyword
keyword
49537
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"